Literature DB >> 6240150

The effect of previous endocrine therapy on responses to a single dose of an LHRH analogue.

J M Allen, G Williams, J P O'Shea, C Smith, T Yeo, D Kerle, S R Bloom.   

Abstract

Serum concentrations of gonadotropins, testosterone and dehydrotestosterone were determined in patients receiving conventional endocrine therapy for advanced metastatic adenocarcinoma of prostate. The effect over 4 h of a single dose of a long acting analogue of LHRH was determined in these patients and compared to the response in patients receiving the analogues as first choice of treatment. Oestrogen therapy was found to suppress basal and stimulated gonadotropins and testicular androgens. Cyproterone therapy only partially reduced basal hormone concentrations and the response to the LHRH analogue was delayed. Orchidectomy resulted in elevated gonadotropins and an exaggerated response to the analogue. As patients who relapse while failing conventional therapy, may subsequently be treated by further endocrine manipulation, precise determination of their endocrine status should predict any expected benefit. Patients previously treated with stilboestrol are unlikely to respond to orchidectomy or LHRH analogue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6240150     DOI: 10.1007/bf00256149

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  10 in total

1.  Clomiphene citrate in men: increase of cortisol, luteinizing hormone, testosterone and steroid-binding globulins.

Authors:  J C Marshall; D C Anderson; C W Burke; A Galvao-Teles; T R Fraser
Journal:  J Endocrinol       Date:  1972-05       Impact factor: 4.286

2.  Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.

Authors:  J M Allen; J P O'Shea; K Mashiter; G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-05-21

3.  Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.

Authors:  J M Allen; D J Kerle; H Ware; A Doble; G Williams; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1983-12-10

4.  Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.

Authors:  D Kerle; G Williams; H Ware; A Doble; J Allen; S R Bloom
Journal:  Br J Urol       Date:  1984-10

5.  Serum testosterone and dihydrotestosterone changes with age in rat.

Authors:  R Ghanadian; J G Lewis; G D Chisholm
Journal:  Steroids       Date:  1975-06       Impact factor: 2.668

6.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.

Authors:  G Tolis; D Ackman; A Stellos; A Mehta; F Labrie; A T Fazekas; A M Comaru-Schally; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

7.  Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?

Authors:  V Borgmann; W Hardt; M Schmidt-Gollwitzer; H Adenauer; R Nagel
Journal:  Lancet       Date:  1982-05-15       Impact factor: 79.321

8.  The diagnosis of oestrogen escape and the role of secondary orchiectomy in prostatic cancer.

Authors:  A R Stone; T B Hargreave; G D Chisholm
Journal:  Br J Urol       Date:  1980-12

9.  The clinical spectrum of prostate cancer.

Authors:  R de Vere White; D F Paulson; J F Glenn
Journal:  J Urol       Date:  1977-03       Impact factor: 7.450

10.  Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.

Authors:  J H Waxman; J A Wass; W F Hendry; H N Whitfield; G M Besser; J S Malpas; R T Oliver
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.